Navigation Links
Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction

atening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including that the final results of our bioequivalence study will be consistent with the top-line results received to date and those described in the Annual Report on Form 10-K that the Company has filed with the U.S. Securities and Exchange Commission ("SEC") reporting its financial position and results of operations as of and for the year ended December 31, 2006, could adversely affect the Company's ability to obtain these results. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany, Chief Executive Officer, +1-305-529-2522,, or Jack Weinstein, Chief Financial Officer,+1-201-934-4201, , both of CatalystPharmaceutical Partners; media, Tina Posterli, Rx Communications Group,+1-917-322-2565, pmcenany@catalystpharma.com jweinstein@catalystpharma.com tposterli@rxir.com

Web site: http://www.catalystpharma.com//

Ticker Symbol: (NASDAQ-NMS:CPRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All ri
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Materia Licenses Metathesis Catalyst Platform to Eisai
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/6/2015)... -- IGI Laboratories, Inc. (NYSE-MKT: IG), a New Jersey ... today at the Deutsche Bank 40th Annual Health Care Conference. ... and 7 th at The InterContinental Hotel, ... CEO and President and Jenniffer Collins , Chief Financial ... 2015, at 3:30 p.m. ET.   The presentation will be ...
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... 2015   Symbiomix Therapeutics today announced multiple ... tranche of a $41 million Series A financing and ... testing a single oral dose of SYM-1219 for the ... the U.S. Food and Drug Administration (FDA) at an ... submit the Phase 2 trial as one of two ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 2Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 5
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... Ace Care, has recently announced that they will now ... replacement, for strata complexes in addition to commercial and ... large scale and require a lot of technical knowledge ... “When we do an installation we will take away ...
(Date:5/6/2015)... Va. (PRWEB) May 06, 2015 ... in the state of Virginia to acquire Intuitive ... surgical robot. The system upgrade includes enhanced surgical ... minimally invasive procedures across a wide spectrum of ... options, reduced pain and quicker recovery times. , ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
(Date:5/6/2015)... The Beryl Institute announces the publication of ... (PXJ), an international, open access, peer-reviewed journal focused on ... experience. The second volume of PXJ supports the goal ... the voices engaged and provides the space for listening, ... The Beryl Institute, Volume 2, Issue 1 includes ...
(Date:5/6/2015)... Animals make just as good friends as they do pets. ... An Ohio veterinarian has been observing this for ... advantages of owning a pet. , “When animals and humans ... there are proven health benefits for people-- including physical, mental ... Animal Medical Center of Streetsboro said. Every May, ...
Breaking Medicine News(10 mins):Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3
... Colo., Sept. 11 ,Spectranetics Corporation (Nasdaq: SPNC ... A.G. Edwards Growth Conference, which is being held,September ... John G. Schulte, Spectranetics, president and chief executive ... at 9:30 a.m. Eastern time,(7:30 a.m. Mountain time) ...
... Board of Directors of,Bristol-Myers Squibb Company (NYSE: BMY ... per share on the $.10 par value,Common Stock of ... 1, 2007 to stockholders of record at the close ... declared a quarterly dividend of fifty cents ($0.50),per share ...
... Sept. 11 Washington state nursing,leader Sally Watkins, ... of,Nursing Practice, Education, and Research by the Washington ... professional nurses,association and union. "We are very ... leader,who will be a strong patient and nurse ...
... nuclear power industry is riding the green wave back ... solution to our growing energy needs. But even as ... realistically play, it is bound by a global energy ... by the marketplace. , Veteran New York Times ...
... a third of prostate biopsies resulted in a cancer ... Men whose first biopsy did not find cancer often ... chance of a cancer diagnosis. , While PSA ... cancer screening, a biopsy is what actually determines the ...
... at the University of Oregon and requiring no more ... after a doctors appointment is credited with a 224-percent ... mild developmental delays in a yearlong study. , Researchers ... referrals for special services or additional monitoring would not ...
Cached Medicine News:Health News:Spectranetics to Present at The A.G Edwards Growth Conference on September 18 2Health News:New Director of Nursing Practice Named for Nurses Association 2Health News:Trade-offs reveal no clear favorites in alternative energy market 2Health News:Other highlights in the September 11 JNCI 2Health News:Other highlights in the September 11 JNCI 3Health News:Parental surveys boost diagnosis abilities of pediatricians 2Health News:Parental surveys boost diagnosis abilities of pediatricians 3
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... trays to dry trays to specialty vaginal ... Cardinal Health offers the widest offering in ... components that are proven to be safe ... of surgical site infections. Cardinal Health Scrub ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Panel consists of plasma specimens with reactivity ... antibodies to HTLV I and II. This ... and diagnostic laboratories to evaluate their anti-HTLV ... test systems are included for comparative analysis ...
Medicine Products: